# BrightIntel

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/brightintel

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.brightintel.cn
- Latest round: Series A (Oct 31, 2025)
- Investors on record: 2

## About

Founded in 2022 and headquartered in Suzhou, China, Zhiyao Biopharmaceutical (Suzhou) Co., Ltd., trading as BrightIntel specializes in AI-driven drug development. In October 2025, BrightIntel raised Series A funding from new investors Zhongxi Dingchuang and Suzhou Xincheng Private Equity Fund Management.
BrightIntel focuses on the development of innovative drug therapies using AI-driven platforms. Their primary offerings include an AI drug discovery platform that employs deep learning and big data analytics to improve molecular activity predictions, and a proprietary drug delivery technology that enhances therapeutic effectiveness while minimizing side effects. Through these offerings, the company aims to serve pharmaceutical companies and healthcare providers globally, particularly in North America and Europe, with an emphasis on providing safer alternatives to traditional opioid therapies.
BrightIntel generates revenue through strategic collaborations with pharmaceutical companies and healthcare organizations that implement its AI-driven drug discovery and delivery solutions. Its revenue model includes milestone payments based on the developmental phases of drug candidates, alongside potential B2B licensing agreements for its advanced drug delivery systems and AI platforms, particularly focused on pain management therapeutic applications.

## Funding rounds

- Series A, Oct 31, 2025 — Suzhou Xincheng Private Equity Fund Management, Zhongxi Dingchuang

## Investors

- Suzhou Xincheng Private Equity Fund Management (https://capitalatlas.ai/funds/suzhou-xincheng-private-equity-fund-management) — Series A
- Zhongxi Dingchuang — Series A